Celldex
This company (presently owned 100 % by Medarex) has filed an amended S-1 with SEC. Available at
sec.gov
Noteworthy is that the company has now got its first vaccine into the clinic.
HCG-VAC
Our lead product candidate, HCG-VAC, is a cancer vaccine for the treatment of colorectal, pancreatic, bladder and breast cancers that express beta human chorionic gonadotropin, known as bhCG, an antigen primarily found on tumors for these types of cancer. An investigational new drug application became effective in February 2004 for HCG-VAC. Once effective, an investigational new drug application constitutes authorization from the United States Food and Drug Administration, or FDA, to administer an investigational drug or biological product in human clinical trials. HCG-VAC entered a Phase I clinical trial in May 2004 for colorectal, pancreatic and bladder cancers. Phase I clinical trials typically take one to two years to complete. If successful in Phase I clinical trials, our product candidates must also advance through Phase II and Phase III clinical trials, which collectively could take three to six additional years to complete, before our product candidates can be commercialized. As a result, we do not anticipate that our lead product candidate, HCG-VAC, will reach the market until 2010 at the earliest. |
